We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Improvement in Baroreflex Sensitivity in OSAS

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2005 by Nagoya University.
Recruitment status was:  Recruiting
ClinicalTrials.gov Identifier:
First Posted: January 31, 2006
Last Update Posted: January 31, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Nagoya University
Individuals with obstructive sleep apnea syndrome (OSAS) are at high risk for cardiovascular morbidity and mortality. The effect of long-term nocturnal therapy with continuous positive airway pressure (CPAP) on daytime baroreflex sensitivity (BRS), a predictor of cardiac death, was investigated in OSAS patients.

Condition Intervention
Obstructive Sleep Apnea Syndrome Device: continuous positive airway pressure therapy

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Nagoya University:


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • obstructive sleep apnea syndrome

Exclusion Criteria:

  • diabetes mellitus, chronic obstructive lung disease, coronary or valvular heart disease, congestive heart failure, renal failure, or endocrine dysfunction. Moreover, none of them were taking b-blockers, vasodilators, or inotropic agents at the time of enrollment in the study.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00284037

Contact: Akiko Noda, PhD +81-52-719-1537 a-noda@met.nagoya-u.ac.jp

Nagoya University of Health Sciences Recruiting
Nagoya, Japan, 461-8673
Contact: Akiko Noda, PhD    +81-719-1537    a-noda@met.nagoya-u.ac.jp   
Principal Investigator: Akiko Noda, PhD         
Sponsors and Collaborators
Nagoya University
Study Chair: Mitsuhiro Yokota, MD.PhD Department of Cardiovascular Genome Science, Nagoya University School of Medicine, Nagoya, Aichi, Japan
  More Information

ClinicalTrials.gov Identifier: NCT00284037     History of Changes
Other Study ID Numbers: NU-06-A-0003
First Submitted: January 27, 2006
First Posted: January 31, 2006
Last Update Posted: January 31, 2006
Last Verified: May 2005

Keywords provided by Nagoya University:
obstructive sleep apnea,

Additional relevant MeSH terms:
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Respiration Disorders
Respiratory Tract Diseases
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases